评价达格列净治疗胰腺炎相关的初发3c型糖尿病的临床价值  

Evaluation on the Clinical Value of Dapagliflozin in the Treatment of Pancreatitis-related Newly Diagnosed Type 3c Diabetes Mellitus

作　　者：常成爱 王福伟 于忠娟 CHANG Cheng'ai;WANG Fuwei;YU Zhongjuan(The First Department of Internal Medicine,Weifang Sixth People's Hospital,Weifang,Shandong Province,261000 China)

机构地区：[1]潍坊市第六人民医院内一科,山东潍坊261000

出　　处：《糖尿病新世界》2022年第17期108-111,共4页Diabetes New World Magazine

摘　　要：目的 分析胰腺炎相关的初发3c型糖尿病患者接受达格列净的治疗效果。方法 选取2019年1月—2022年2月潍坊市第六人民医院收治的54例胰腺炎相关的初发3c型糖尿病患者为研究对象。采用中心数字分层法分为甲组(27例,二甲双胍)与乙组(27例,达格列净),评价两组临床效果。结果 治疗后,两组患者FPG、2 hPG、HbA1c比较,差异无统计学意义(P>0.05);治疗后,甲组患者TG低于乙组,TC、LDL-C高于乙组,差异有统计学意义(P<0.05);治疗后,两组患者HDL-C比较,差异无统计学意义(P>0.05);治疗后,甲组患者骨密度低于乙组,差异有统计学意义(P<0.05)。结论 胰腺炎相关的初发3c型糖尿病患者接受达格列净能够有效降低患者血糖、血脂,改善骨密度指标,药物安全性可以得到保障。Objective To analyze the therapeutic effect of dapagliflozin in patients with newly diagnosed type 3c diabetes mellitus associated with pancreatitis.Methods A total of 54 patients with pancreatitis related primary type 3c diabetes who were admitted to the Sixth People’s Hospital of Weifang City from January 2019 to February 2022 were selected as the research object.They were divided into group A(27 cases,metformin) and group B(27 cases,dapagliflozin) by central numerical stratification.The clinical effects of the two groups were evaluated.Results After treatment,there was no statistically significant difference in FPG,2 hPG and HbA1c between the two groups(P>0.05).After treatment,TG in group A was lower than that in group B,TC and LDL-C were higher than those in group B,and the difference was statistically significant(P0.05).After treatment,the bone mineral density of patients in group A was lower than that in group B,and the difference was statistically significant(P<0.05).Conclusion Dapagliflozin in patients with newly diagnosed type 3c diabetes mellitus associated with pancreatitis can effectively reduce blood glucose and blood lipids,improve bone mineral density indexes,and the drug safety can be guaranteed.

关 键 词：胰腺炎 初发3c型糖尿病 血脂指标 

分 类 号：R587.1[医药卫生—内分泌]